Key result
Patients with type 2 diabetes had 40% higher circulating betatrophin concentrations compared to matched controls (893 ± 80 vs 639 ± 66 pg/mL).
Why the study?
Are circulating betatrophin concentrations elevated in patients with type 2 diabetes compared to matched controls?
Population
45 individuals, comprising 27 patients with type 2 diabetes and 18 gender-, age-, and BMI-matched controls…
Design
Case-control
Authors
Loading...
Higher betatrophin in type 2 diabetes is hypothesis-generating; leaves open its value as biomarker or therapeutic target.
Case-Control (n=45)
Are circulating betatrophin concentrations elevated in patients with type 2 diabetes compared to matched controls?
Effect estimate: 40% higher
Absolute Event Rate: 893% vs 639%
Circulating betatrophin levels are significantly elevated in patients with type 2 diabetes and insulin resistance compared to matched controls.
Espes et al. (2014) conducted a case-control in Type 2 diabetes (n=45). Type 2 diabetes vs. Gender-, age-, and BMI-matched controls was evaluated on Plasma betatrophin concentrations (40% higher). Patients with type 2 diabetes had 40% higher circulating betatrophin concentrations compared to matched controls (893 ± 80 vs 639 ± 66 pg/mL).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: